New System Can Assess Severity of Von Willebrand Disease

This article originally appeared here.
Share this content:
New System Can Assess Severity of Von Willebrand Disease
New System Can Assess Severity of Von Willebrand Disease

FRIDAY, Feb. 5, 2016 (HealthDay News) -- A new microchip-flow chamber system (T-TAS) can be used to discriminate and predict bleeding score (BS) in type 1 von Willebrand disease (VWD), according to a study published online Jan. 27 in the Journal of Thrombosis and Haemostasis.

Keiji Nogami, M.D., Ph.D., from the Nara Medical University in Japan, and colleagues examined the potential of T-TAS for assessing physiological hemostasis in VWD. Fifty type 1 VWD patients with whole blood samples were assessed with microchips coated with collagen (PL-chip) or collagen/thromboplastin (AR-chip) to examine platelet thrombus formation (PTF) at high-shear rates or fibrin-rich PTF at low-shear rates. Flow pressure curves were used to calculate the times to increase 10 and 30 kPa (T10 and T30) from baseline. A standardized questionnaire was used to determine BS.

The researchers found that irrespective of the flow rate, PL-T10 values correlated with BS better than von Willebrand factor-ristocetin cofactor activity, while there was a weak correlation for AR-T10 with BS. Lower levels of VWF and higher BS were seen for patients with PL-T10 >10 minutes or AR-T10 >30 minutes, compared to those with PL-T10 ≤10 minutes or AR-T10 ≤30 minutes, with the greater difference observed with PL-T10. The best correlation for clinical severity was seen with PL-T10 >8 minutes.

"T-TAS could be a useful technique for discriminating and predicting the BS in VWD type 1 patients," the authors write.

One author is employed by the Fujimori Kogyo Co., the manufacturer of T-TAS.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »